| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 05/23/2013 | US20130131063 Compounds and Methods for Inhibiting the Interaction of BCL Proteins with Binding Partners |
| 05/23/2013 | US20130131060 3-(indolyl)- or 3-(azaindolyl)- 4-arylmaleimide compounds and their use in tumor treatment |
| 05/23/2013 | US20130131057 New bicyclic compounds as pi3-k and mtor inhibitors |
| 05/23/2013 | US20130131055 Furopyridinyl-substituted 1,4-dihydropyridine derivatives and methods of use thereof |
| 05/23/2013 | US20130131052 Amelioration Of The Development Of Cataracts And Other Ophthalmic Diseases |
| 05/23/2013 | US20130131036 Novel trpv3 modulators |
| 05/23/2013 | US20130131028 Methods for treatment of sleep-related breathing disorders |
| 05/23/2013 | US20130131018 Substituted isoquinolines and their use as tubulin polymerization inhibitors |
| 05/23/2013 | US20130131017 Boron-containing small molecules |
| 05/23/2013 | US20130131010 Galactose-pronged polysaccharides in a formulation for antifibrotic therapies |
| 05/23/2013 | US20130131002 Compositions and methods for treating pulmonary hypertension |
| 05/23/2013 | US20130130998 Analogues of Etoposide for the Treatment of Tumours |
| 05/23/2013 | US20130130995 Treatments for Gastrointestinal Disorders |
| 05/23/2013 | US20130130981 Treatment using neublastin polypeptides |
| 05/23/2013 | US20130130974 NOVEL SYNTHETIC APPROACH TO beta-AMINOBUTYRYL SUBSTITUTED COMPOUNDS |
| 05/23/2013 | US20130130971 Method for Inhibiting HIV Replication in Mammal and Human Cells |
| 05/23/2013 | US20130129841 Therapeutic combination comprising a parp-1 inhibitor and an anti-neoplastic agent |
| 05/23/2013 | US20130129840 Combination therapy using a ruthenium complex |
| 05/23/2013 | US20130129809 Compositions and methods for treating and preventing cancer by targeting and inhibiting cancer stem cells |
| 05/23/2013 | US20130129795 Inhibition and dispersion of bacterial biofilms with imidazole-triazole derivatives |
| 05/23/2013 | US20130129790 Adjuvant Incorporation in Immunonanotherapeutics |
| 05/23/2013 | US20130129789 Anti-bacterial applications of poly-n-acetylglucosamine nanofibers |
| 05/23/2013 | US20130129768 Treatment or prevention of infection |
| 05/23/2013 | US20130129751 Method for treating prostatitis utilizing pore-forming protein proaerolysin |
| 05/23/2013 | US20130129742 Human leukolectins and uses thereof |
| 05/23/2013 | US20130129738 Pharmaceutical composition |
| 05/23/2013 | US20130129735 Antibodies to egfl7 and methods for their use |
| 05/23/2013 | US20130129734 Composition and methods for the diagnosis, prognosis and treatment of leukemia |
| 05/23/2013 | US20130129733 Humanized anti-egfl7 antibodies and methods using same |
| 05/23/2013 | US20130129729 Compositions comprising cross-species-specific antibodies and uses thereof |
| 05/23/2013 | US20130129720 Combination Cancer Therapies with Wortmannin Analogs |
| 05/23/2013 | US20130129718 Purification of anti-c-met antibodies |
| 05/23/2013 | US20130129698 Conjugated blood coagulation factor viia |
| 05/23/2013 | US20130129695 Methods for treating or inhibiting infection by clostridium difficile |
| 05/23/2013 | US20130129689 Agent derived from tortoise spleen stimulating mammalian hemopoiesis |
| 05/23/2013 | US20130129677 Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections |
| 05/23/2013 | US20130129676 Combination of anti-envelope antibodies and anti-receptor antibodies for the treatment and prevention of hcv infection |
| 05/23/2013 | US20130129675 Interferon therapies in combination with blockade of stat3 activation |
| 05/23/2013 | US20130129671 Tripeptides Incorporating Deuterium as Inhibitors of Hepatitis C Virus |
| 05/23/2013 | US20130129670 Macrophage activating factor for use in the treatment of chronic fatigue syndrome (cfs) and cfs-related diseases and disorders |
| 05/23/2013 | US20130129662 Compositions and Methods for the Treatment of Heart Failure |
| 05/23/2013 | US20130129660 Compositions and methods for treating or preventing gastrointestinal disorders and gerd-related respiratory disorders |
| 05/23/2013 | US20130129617 Method for Treating Psoriatic Arthritis By Administering An Anti-IL-12 Antibody |
| 05/23/2013 | US20130125887 Crystalline forms of a biphenyl compound |
| 05/23/2013 | US20130125886 Method of preventing adverse effects by glp-1 |
| 05/23/2013 | US20130125884 Novel dosage and formulation |
| 05/23/2013 | CA2856016A1 Agent for treating fibrosis of the intestine |
| 05/23/2013 | CA2855954A1 Compositions comprising an aryl pyrazole and a substituted imidazole, methods and uses thereof |
| 05/23/2013 | CA2855619A1 Combination of a phosphoinositide 3-kinase inhibitor and a modulator of the janus kinase 2 - signal transducer and activator of transcription 5 pathway |
| 05/22/2013 | EP2594642A1 Induction of exon skipping in eukaryotic cells |
| 05/22/2013 | EP2594641A1 Induction of exon skipping in eukaryotic cells |
| 05/22/2013 | EP2594640A1 Induction of exon skipping in eukaryotic cells |
| 05/22/2013 | EP2594589A1 ANTI-Trop-2 ANTIBODY |
| 05/22/2013 | EP2594280A1 Activin neutralisers and uses thereof for treatment of diseases associated with aberrant "host defence response" activation |
| 05/22/2013 | EP2594274A1 Novel hyaluronic acid decomposition-promoting factor and inhibitor thereof |
| 05/22/2013 | EP2594271A1 2-[(3,5-difluoro-3'-methoxy-1,1'-biphenyl-4-yl)amino]nicotinic acid for the treatment of psoriasis. |
| 05/22/2013 | EP2594270A2 The use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc) |
| 05/22/2013 | EP2594267A1 Protective Agent for Retinal Nerve or Optic Nerve |
| 05/22/2013 | EP2594262A1 Substrate of three-layer structure and water-containing adhesive patch including same |
| 05/22/2013 | EP2593482A2 A combination pharmaceutical composition and methods of treating diseases or conditions associated with the cardiovascular system |
| 05/22/2013 | EP2593139A2 Administration of hypoxia activated prodrugs and antiangiogenic agents for the treatment of cancer |
| 05/22/2013 | EP2593108A2 Pharmaceutical compositions comprising r(+) budesonide and one or more bronchodilators |
| 05/22/2013 | EP2593106A1 Organic compounds |
| 05/22/2013 | EP2593104A2 Methods of treating and preventing/reducing the likelihood of mesial temporal lobe epilepsy (tle) |
| 05/22/2013 | EP2593103A2 Reducing transmission of sexually transmitted infections |
| 05/22/2013 | EP2593093A1 Use of a cationic amphiphilic drug for the preparation of a formulation for the reduction of subcutaneous adipose tissue |
| 05/22/2013 | EP2593085A1 Dual drug delivery using silicone gels |
| 05/22/2013 | EP2086535B1 Angiotensin ii receptor antagonist for the treatment of systemic diseases in cats |
| 05/22/2013 | CN1729012B Composition for treating solid tumors |
| 05/22/2013 | CN103119066A Compound having activity for inhibiting tgf- belta receptor activation, method for screening same, and composition for prevention or treatment of hepatitis c virus-induced diseases |
| 05/22/2013 | CN103118674A Xenon-based anesthetic gas composition usable during an endarterectomy involving the clamping of the carotid artery |
| 05/22/2013 | CN103118661A Method for controlling hair growth, method for selecting or evaluating hair growth control agent, and hair growth suppression agent |
| 05/22/2013 | CN103114087A RNA(Ribonucleic Acid)and application thereof in diseases of cardiovascular system |
| 05/22/2013 | CN103113303A Nitrogen heterocyclic compound used as CRTH2 (Chemoattractant Receptor-Homologous Molecule Expressed on Th2 Cells) receptor antagonist |
| 05/22/2013 | CN103110957A Graphene oxide drug carrier as well as preparation method and application thereof |
| 05/22/2013 | CN103110954A Cholesterol-modified biodegradable polycation carrier as well as preparation method and application thereof |
| 05/22/2013 | CN103110952A Microwave-assisted preparation method of hydroxylapatite nanometer structure porous microspheres |
| 05/22/2013 | CN103110951A Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective rtk inhibitors |
| 05/22/2013 | CN103110950A Application of medicinal composition |
| 05/22/2013 | CN103110949A Ribavirin small-capacity injection preparation and preparation method thereof |
| 05/22/2013 | CN103110948A Antineoplastic combinations with mTOR inhibitor,herceptin, and/or HKI-272 |
| 05/22/2013 | CN103110947A Additive used for activating platelets |
| 05/22/2013 | CN103110944A Methods of administering anti-TNF alpha antibodies |
| 05/22/2013 | CN103110619A Application of vitexin in preparing drug with cough and asthma relieving action |
| 05/22/2013 | CN103110611A Inhalant, preparation method thereof, and application of inhalantas inhalant carrier with pullulan |
| 05/22/2013 | CN103110610A Mouth mucosa sustained-release preparation for treating oral and periodontal diseases by chlorhexidine |
| 05/22/2013 | CN103110577A SMANCS (Styrene Maleic Acid Neocarzinostatin) oily preparation, preparation method and application |
| 05/22/2013 | CN102245211B Combined drug administration |
| 05/22/2013 | CN101947223B Composite anesthetic, preparation method thereof, and use thereof in myocardial infarction animal model |
| 05/22/2013 | CN101921220B Pharmaceutical compositions for treating diseases with bone mass loss having EP4 agonist as the active ingredient |
| 05/22/2013 | CN101843614B Application of metronidazole or its pharmacologically acceptable derivative |
| 05/22/2013 | CN101778934B CD34 stem cell-related methods and compositions |
| 05/22/2013 | CN101766818B Polysaccharide gold-magnetic composite particle medicine carrier and preparation method thereof |
| 05/21/2013 | US8445694 Hydrazonopyrazole derivatives and their use as therapeutics |
| 05/21/2013 | US8445644 ErbB interface peptidomimetics and methods of use thereof |
| 05/21/2013 | US8445535 Use of medium chain triglycerides for the treatment and prevention of Alzheimer's disease and other diseases resulting from reduced neuronal metabolism II |
| 05/21/2013 | US8445513 α-Aminoamide derivatives useful in the treatment of restless legs syndrome |
| 05/21/2013 | US8445287 Method and apparatus for determining anticoagulant therapy factors |
| 05/21/2013 | US8445268 Her-2/neu DNA vaccine having anti-cancer activity |
| 05/21/2013 | US8445237 RNA interference mediating small RNA molecules |